The impact of universal varicella vaccination on the clinical burden of varicella in Colombia: A National database Analysis, 2008–2019

Pawaskar, Manjiri; Gil-Rojas, Yaneth; Parellada, C.; Beltrán, Claudia Ximena Herrera; Prieto, E.; Lasalvia, Pieralessandro

doi:10.1016/j.vaccine.2022.07.012

Cited by 8 publications

(2 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It has been hypothesized that decreased virus circulation following varicella vaccination implementation and the resultant diminished exogenous boosting could potentially impact on the epidemiology of HZ. 56–59 However, there is no consistent evidence showing an extensive surge in HZ incidence after varicella vaccination implementation, 60–63 the recent first-dose coverage rates of which are 66% (Brazil, 2021), 64 72% (Argentina, 2020), 65 79% (Chile, 2022), 66 and 93% (Colombia, 2019), 67 while varicella vaccination is not included in the universal mass vaccination program in Mexico. Instead, the key contributing factor to HZ is immune senescence in older adults.…”

Section: Discussionmentioning

confidence: 99%

How large could the public health impact of introducing recombinant zoster vaccination for people aged ≥50 years in five Latin American countries be?

Han

Gómez²,

Veras

et al. 2023

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

This study aimed to: (1) estimate the disease burden of herpes zoster (HZ) and (2) assess the potential public health impact of introducing adjuvanted recombinant zoster vaccine (RZV) compared with no vaccination in adults aged ≥50 years in Argentina, Brazil, Mexico, Chile, and Colombia using the ZOster ecoNomic Analysis (ZONA) static multicohort Markov model. The model followed individuals aged ≥50 years from administration of RZV over their remaining lifetime. Inputs were based, most often, on local data. First dose coverage was assumed to be 35%, with 75% second dose compliance. It was predicted that without RZV, there would be 23,558,675 HZ cases, 6,115,981 post-herpetic neuralgia (PHN) cases, and 7,058,779 non-PHN complications in the five countries, but introducing RZV under assumed coverage could avoid 4,583,787 (19%) HZ cases, 1,130,751 (18%) PHN cases, and 1,373,419 (19%) non-PHN complications. Also, 10427,504 (20%) doctor’s office visits and 1,630,201 (19%) days of hospitalization could be averted in the three countries (Argentina, Brazil, and Mexico) with available input data. The numbers needed to be vaccinated to avoid one case of HZ were 9–10 across countries, and to avoid one case of PHN, 35–40. One-way sensitivity analyses showed that the input parameters with the largest impact on the estimated number of HZ cases avoided were first dose coverage, initial HZ incidence, and vaccine efficacy waning. In conclusion, the introduction of RZV for older adults in Latin America could greatly reduce the public health burden of HZ and reduce the related doctor visits and hospitalization days.

show abstract

Section: Discussionmentioning

confidence: 99%

How large could the public health impact of introducing recombinant zoster vaccination for people aged ≥50 years in five Latin American countries be?

Han

Gómez²,

Veras

et al. 2023

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

show abstract

“…Other studies have previously evaluated the impact of UVV in Latin America [ 22 , 23 , 25 , 37 ]. The findings of this study are consistent with those reported in a previous ecological study conducted in Argentina from 2008 to 2017.…”

Section: Discussionmentioning

confidence: 99%

Trends in Varicella Burden of Disease Following Introduction of Routine Childhood Varicella Vaccination in Argentina: A 12-Year Time Series Analysis

Giglio

Lasalvia²,

Pawaskar

et al. 2022

Vaccines

Self Cite

View full text Add to dashboard Cite

One-dose universal varicella vaccination (UVV) was introduced in the Argentinian National Immunization Program in July 2015. This study examined the impact of one-dose UVV on varicella incidence and mortality in Argentina. Incidence and mortality data were obtained from official databases for pre-UVV (January 2008–June 2015) and post-UVV (July 2015–December 2019) periods. Time series analyses with autoregressive integrated moving average (ARIMA) modeling predicted varicella incidence and mortality in absence of UVV in the target (aged 1–4 years) and overall population. Predicted and observed values post-UVV were compared to estimate UVV impact. Mean annual incidence rates per 100,000 reduced from 1999 (pre-UVV) to 1122 (post-UVV) in the target population and from 178 to 154 in the overall population. Significant declines in incidence were observed, reaching reductions of 83.9% (95% prediction interval [PI]: 58.9, 90.0) and 69.1% (95% PI: 23.6, 80.7) in the target and overall populations, respectively, during peak months (September-November) post-UVV. Decreasing trends in mortality rate from 0.4 to 0.2 per 1,000,000 population were observed. Over the last four years, one-dose UVV has significantly reduced varicella burden of disease in Argentina. Continuous efforts to improve vaccination coverage rates and long-term follow-up are needed to better understand the benefits of the UVV program.

show abstract

Determining factors associated with vaccination coverage in the first year of life in Brazil (2013−2022)

Lui,

Réquia,

dos Santos

et al. 2024

Vaccine

View full text Add to dashboard Cite

The impact of universal varicella vaccination on the clinical burden of varicella in Colombia: A National database Analysis, 2008–2019

Cited by 8 publications

References 24 publications

How large could the public health impact of introducing recombinant zoster vaccination for people aged ≥50 years in five Latin American countries be?

How large could the public health impact of introducing recombinant zoster vaccination for people aged ≥50 years in five Latin American countries be?

Trends in Varicella Burden of Disease Following Introduction of Routine Childhood Varicella Vaccination in Argentina: A 12-Year Time Series Analysis

Determining factors associated with vaccination coverage in the first year of life in Brazil (2013−2022)

Contact Info

Product

Resources

About